Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 1/2016

01-01-2016 | Research Article

Endostatin exerts radiosensitizing effect in non-small cell lung cancer cells by inhibiting VEGFR2 expression

Authors: L. Liu, Y. Qiao, C. Hu, Y. Liu, Y. Xia, L. Wang, B. Liu, H. Chen, X. Jiang

Published in: Clinical and Translational Oncology | Issue 1/2016

Login to get access

Abstract

Background

To determine the effects of endostatin on vascular growth factor receptor 2 (VEGFR2) expression in non-small cell lung cancer (NSCLC) cells and the mechanisms underlying its radiosensitizing effect.

Methods

VEGFR2 mRNA levels were determined in different NSCLC cell lines using qRT-PCR. RT-PCR and Western blot assays were used to assess the expression of mRNA and proteins. The radiosensitivity of the cells was determined by colony-formation assays; and cell apoptosis and cell cycle distribution were determined by flow cytometry.

Results

VEGFR2 mRNA levels differed among the five NSCLC cell lines (P < 0.01), with the highest expression in Calu-1 cells and lowest in A549 cells. Endostatin significantly inhibited the growth of Calu-1 cells (P < 0.01) (IC20 = 296.5 μg/ml), and the expression of VEGFR2 and HIF-1α (P < 0.05). Phosphorylation of protein kinase B (Akt), extracellular signal-regulated kinases 1/2 (ERK1/2), and p38 were significantly lower in endostatin-treated cells than control (P < 0.05). Endostatin enhanced the radiosensitivity of Calu-1 cells to SER = 1.38 and induced apoptosis (P < 0.01) and G2/M blockage (P < 0.01). However, endostatin had limited effects on A549 cells. Compared with Calu-1 cells, there was not significantly effects on cell radiosensitivity (SER = 1.09).

Conclusions

Endostatin induces apoptosis and enhances radiosensitivity of the VEGFR2 high-expressing cell line Calu-1, but it has a limited effect on the VEGFR2 low-expressing cell line A549.
Literature
1.
Yeo SG, Kim ES. Efficient approach for determining four-dimensional computed tomography-based internal target volume in stereotactic radiotherapy of lung cancer[J]. Radiat Oncol J. 2013;31(4):247–51.PubMedPubMedCentralCrossRef
2.
Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol. 2010;94:1–11.PubMedCrossRef
3.
Langendorff H, Koch R. Studies on biological radioprotection. IX. Effect of SH-blockers on radiosensitivity. Strahlentherapie. 1954;95(4):535–41.PubMed
4.
Jiang X-D, Qiao Y, Dai P, Wu J, Song D-A, Li S-Q, et al. Preliminary clinical study of weekly recombinant human endostatin as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of NSCLC. Clin Transl Oncol. 2012;14(6):465–70.PubMedCrossRef
5.
Jiang X-D, Ding M-H, Qiao Y, Liu Y, Liu L. Study on lung cancer cells expressing VEGFR2 and the impact on the effect of RHES combined with radiotherapy in the treatment of brain metastases. Clin Lung Cancer. 2014;15(2):e23–9.PubMedCrossRef
6.
Donnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund L-T, Bremnes RM. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer. 2010;116:4318–25.PubMedCrossRef
7.
Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, et al. Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness. Histopathology. 2012;61:350–64.PubMedCrossRef
8.
Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B, et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis. 2013;4:e544.PubMedPubMedCentralCrossRef
9.
Yang F, Tang X, Riquelme E, Behrens B, Nilsson MB, Giri U, Tang X, et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011;71(16):5512–21.PubMedPubMedCentralCrossRef
10.
Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol. 2002;64(5–6):993–8.PubMedCrossRef
11.
12.
Kim Y-M, Hwang S, Kim Y-M, Pyun B-J, Kim T-Y, Lee S-T, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.[J]. J Biol Chem. 2002;277(31):27872–9.PubMedCrossRef
13.
Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities(and problems)for cancer therapy[J]. Cancer Res. 1998;58(7):1408–16.PubMed
14.
Meijer TWH, Kaanders JHAM, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012;18(20):5585–94.PubMedCrossRef
15.
Agani F, Jiang B-H. Oxygen-independent regulation of HIF-1: novel involvement of PI3 K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets. 2013;13:245–51.PubMedCrossRef
16.
Karapetsas A, Giannakakis A, Pavlaki M, Panayiotidis M, Sandaltzopoulos R, Alex Galanis. Biochemical and molecular analysis of the interaction between ERK2 MAP kinase and hypoxia inducible factor-1α. Int J Biochem Cell Biol. 2011;43(11):1582–90.PubMedCrossRef
17.
Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, et al. The Kaposi’s sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 2000;60(17):4873–80.PubMed
18.
Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem. 2003;278(16):14013–9.PubMedPubMedCentralCrossRef
19.
Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, et al. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene. 2010;29(20):2938–49.PubMedCrossRef
Metadata
Title
Endostatin exerts radiosensitizing effect in non-small cell lung cancer cells by inhibiting VEGFR2 expression
Authors
L. Liu
Y. Qiao
C. Hu
Y. Liu
Y. Xia
L. Wang
B. Liu
H. Chen
X. Jiang
Publication date
01-01-2016
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 1/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1319-6

Other articles of this Issue 1/2016

Clinical and Translational Oncology 1/2016 Go to the issue

Research Article

Potential impact of (rs 4645878) BAX promoter −248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients

Research Article

SOX4 is a potential prognostic factor in human cancers: a systematic review and meta-analysis

Research Article

Patients with brain metastases derived from gastrointestinal cancer: clinical characteristics and prognostic factors

Research Article

Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis

Research Article

Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)

Research Article

Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits